Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

被引：46

作者：

Alosaimy, Sara ^{[1
]}

Jorgensen, Sarah C. J. ^{[1
,12
]}

Lagnf, Abdalhamid M. ^{[1
]}

Melvin, Sarah ^{[1
]}

Mynatt, Ryan P. ^{[2
,13
]}

Carlson, Travis J. ^{[3
,14
]}

Garey, Kevin W. ^{[3
]}

Allen, David ^{[4
]}

Venugopalan, Veena ^{[5
]}

Veve, Michael ^{[6
,7
]}

Athans, Vasilios ^{[8
]}

Saw, Stephen ^{[8
]}

Yost, Christine N. ^{[9
]}

Davis, Susan L. ^{[1
,10
]}

Rybak, Michael J. ^{[1
,2
,11
]}

机构：

[1] Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI USA

[2] Detroit Med Ctr, Dept Pharm Serv, Detroit, MI USA

[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA

[4] Inova Fairfax Med Campus, Dept Pharm, Falls Church, VA USA

[5] Univ Florida, Coll Pharm, Gainesville, FL USA

[6] Univ Tennessee, Coll Pharm, Knoxville, TN USA

[7] Univ Tennessee, Med Ctr, Knoxville, TN USA

[8] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[9] Beaumont Hosp, Royal Oak, MI USA

[10] Henry Ford Hosp, Dept Pharm, Detroit, MI 48202 USA

[11] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA

[12] Mt Sinai Hosp, Toronto, ON, Canada

[13] Univ Kentucky Healthcare, Lexington, KY USA

[14] High Point Univ, Fred Wilson Sch Pharm, High Point, NC USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 03期

关键词：

carbapenem-resistant Enterobacteriaceae; Gram-negative infections; meropenem-vaborbactam; multidrug-resistant; SEVERE SEPSIS;

D O I：

10.1093/ofid/ofaa051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

引用

页数：4

共 15 条

[1]

[Anonymous], Healthcare-associated infections (HAIs)

[2] Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group [J].

Doi, Yohei ;

Bonomo, Robert A. ;

Hooper, David C. ;

Kaye, Keith S. ;

Johnson, James R. ;

Clancy, Cornelius J. ;

Thaden, Joshua T. ;

Stryjewski, Martin E. ;

van Duin, David .

CLINICAL INFECTIOUS DISEASES, 2017, 64 :S30-S35

[3] Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention [J].

Gupta, Neil ;

Limbago, Brandi M. ;

Patel, Jean B. ;

Kallen, Alexander J. .

CLINICAL INFECTIOUS DISEASES, 2011, 53 (01) :60-67

[4] A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae [J].

Gutierrez-Gutierrez, Belen ;

Salamanca, Elena ;

de Cueto, Marina ;

Hsueh, Po-Ren ;

Viale, Pierluigi ;

Ramon Pano-Pardo, Jose ;

Venditti, Mario ;

Tumbarello, Mario ;

Daikos, George ;

Pintado, Vicente ;

Doi, Yohei ;

Francisco Tuon, Felipe ;

Karaiskos, Ilias ;

Machuca, Isabel ;

Schwaber, Mitchell J. ;

Azap, Ozlem Kurt ;

Souli, Maria ;

Roilides, Emmanuel ;

Pournaras, Spyros ;

Akova, Murat ;

Perez, Federico ;

Bermejo, Joaquin ;

Oliver, Antonio ;

Almela, Manel ;

Lowman, Warren ;

Almirante, Benito ;

Bonomo, Robert A. ;

Carmeli, Yehuda ;

Paterson, David L. ;

Pascual, Alvaro ;

Rodriguez-Bano, Jesus .

MAYO CLINIC PROCEEDINGS, 2016, 91 (10) :1362-1371

[5] Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae [J].

Jorgensen, Sarah Christina Jane ;

Rybak, Michael Joseph .

PHARMACOTHERAPY, 2018, 38 (04) :444-461

[6] Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial [J].

Kaye, Keith S. ;

Bhowmick, Tanaya ;

Metallidis, Symeon ;

Bleasdale, Susan C. ;

Sagan, Olexiy S. ;

Stus, Viktor ;

Vazquez, Jose ;

Zaitsev, Valerii ;

Bidair, Mohamed ;

Chorvat, Erik ;

Dragoescu, Petru Octavian ;

Fedosiuk, Elena ;

Horcajada, Juan P. ;

Murta, Claudia ;

Sarychev, Yaroslav ;

Stoev, Ventsislav ;

Morgan, Elizabeth ;

Fusaro, Karen ;

Griffith, David ;

Lomovskaya, Olga ;

Alexander, Elizabeth L. ;

Loutit, Jeffery ;

Dudley, Michael N. ;

Giamarellos-Bourboulis, Evangelos J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (08) :788-799

[7] APACHE-II - A SEVERITY OF DISEASE CLASSIFICATION-SYSTEM [J].

KNAUS, WA ;

DRAPER, EA ;

WAGNER, DP ;

ZIMMERMAN, JE .

CRITICAL CARE MEDICINE, 1985, 13 (10) :818-829

[8] Severe Cutaneous Adverse Reactions Related to Systemic Antibiotics [J].

Lin, Ying-Fang ;

Yang, Chih-Hsun ;

Sindy, Hu ;

Lin, Jing-Yi ;

Hui, Chung-Yee Rosaline ;

Tsai, Yun-Chen ;

Wu, Ting-Shu ;

Huang, Ching-Tai ;

Kao, Kuo-Chin ;

Hu, Han-Chung ;

Chiu, Cheng-Hsun ;

Hung, Shuen-Iu ;

Chung, Wen-Hung .

CLINICAL INFECTIOUS DISEASES, 2014, 58 (10) :1377-1385

[9] A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? [J].

Lodise, Thomas P. ;

Zhao, Qi ;

Fahrbach, Kyle ;

Gillard, Patrick J. ;

Martin, Amber .

BMC INFECTIOUS DISEASES, 2018, 18

[10] Impact of Source Control in Patients With Severe Sepsis and Septic Shock [J].

Luisa Martinez, Maria ;

Ferrer, Ricard ;

Torrents, Eva ;

Gtiillamat-Prats, Raquel ;

Goma, Gemma ;

Suarez, David ;

Alvarez-Rocha, Luis ;

Pozo Laderas, Juan Carlos ;

Martin-Loeches, Ignacio ;

Levy, Mitchell M. ;

Artigas, Antonio .

CRITICAL CARE MEDICINE, 2017, 45 (01) :11-19

← 1 2 →